Low hemoglobin predicts high-platelet reactivity and major cardiovascular ischemic events at long-term follow-up among ACS patients receiving dual antiplatelet therapy with ticagrelor.
Monica VerdoiaRoberta RollaPatrizia PergoliniRocco GiosciaMatteo NardinFederica NegroFilippo ViglioneHarry SuryapranataElvin KedhiGiuseppe De Lucanull nullPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2021)
In the present study, we demonstrated that among patients on DAPT with ASA and ticagrelor after PCI for ACS, lower Hb levels are independently associated with a higher rate of HRPR and an increased rate of major ischemic events, and especially for recurrent ACS, although with no impact on survival. Neutral prognostic effect of HRPR was observed across Hb tertiles.
Keyphrases
- acute coronary syndrome
- antiplatelet therapy
- percutaneous coronary intervention
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute myocardial infarction
- ischemia reperfusion injury
- coronary artery bypass grafting
- heart failure
- coronary artery bypass
- oxidative stress
- coronary artery disease
- free survival
- atrial fibrillation
- blood brain barrier
- left ventricular